When did semaglutide come off the shortage list?
February 21, 2025.
Can 503A pharmacies still compound semaglutide?
Yes, for individual patients with documented clinical justification.
Why did the FDA take semaglutide off the shortage list?
Novo Nordisk's Catalent acquisition and capacity expansions brought supply into line with demand by late 2024.
Is compounded semaglutide still legal in 2026?
Yes, through 503A pharmacies with valid patient-specific prescriptions documenting clinical reason.
Will the FDA ban all compounded semaglutide?
An outright ban would require Congressional action; no such legislation is pending.
What clinical reasons justify compounded semaglutide?
Allergen sensitivity, dose strengths not commercially available, concentration adjustments, preservative-free formulation.
Does FormBlends still offer compounded semaglutide?
Yes, through 503A pharmacy partners with documented clinical justification.
Is compounded semaglutide the same as Ozempic?
Same active ingredient, different finished product, not regulatorily equivalent.
What should I do if I'm currently on compounded semaglutide?
Discuss documented justification with your prescriber and evaluate brand self-pay alternatives.
Related guides
- Is Semaglutide Going Away? The Brand vs Compounded Distinction in 2026
- Is Compounded Tirzepatide Going Away? What Actually Changed in October 2024
- Is Tirzepatide Going Away? Brand vs Compounded Availability in 2026
- What's the Lowest Cost Semaglutide Option in 2026? Brand-Name vs Compounded Pricing Explained
- What Is the Most Affordable Semaglutide Option in 2026? (Brand vs Compounded vs Assistance Programs)
- How Much Does Compounded Semaglutide Cost in 2026? Real Pricing From Every Major Source
Sources
- FDA Drug Shortage List update, February 21, 2025, resolving semaglutide shortage
- FDA Guidance Document, "Compounding Animal Drugs From Bulk Drug Substances," and related compounding guidance for human drugs
- Federal Food, Drug, and Cosmetic Act Section 503A, 21 U.S.C. § 353a
- Novo Holdings press release, Catalent acquisition completion, December 2024
- Wilding JPH et al., "Once-Weekly Semaglutide in Adults with Overweight or Obesity," New England Journal of Medicine, March 2021 (STEP 1)
- Rubino D et al., "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance," JAMA, April 2021 (STEP 4)
- USP General Chapter 797, Pharmaceutical Compounding - Sterile Preparations, 2023 revision
- Novo Nordisk NovoCare Wegovy Self-Pay program announcement, 2025
- FDA Drug Safety Communication on compounded semaglutide products, 2024 and 2025 updates
- Endocrine Society Clinical Practice Guideline on Obesity, 2023
- National Association of Boards of Pharmacy compounding standards, 2024
- Outsourcing Facilities Association v. FDA ruling, Northern District of Texas, March 5, 2025 (tirzepatide precedent)
- Novo Nordisk Q4 2024 manufacturing capacity report
- Food and Drug Administration Modernization Act of 1997 (Pub. L. 105-115)
Footer disclaimers
Platform Disclaimer. FormBlends connects patients with licensed clinicians and 503A compounding pharmacies. We are not a pharmacy and we do not practice medicine. All prescribing and dispensing decisions rest with licensed professionals operating under their own state authority.
Get compounded semaglutide, first month $99, then $190 per month, or $165 per month with Subscribe & Save
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Compounded Medication Notice. Compounded semaglutide is prepared by a licensed pharmacy for an individual patient based on a valid prescription with documented clinical justification. It is not FDA-approved. It is not bioequivalent or interchangeable with brand Ozempic, Wegovy, or Rybelsus in any regulatory sense. Clinical trial data for semaglutide applies to the Novo Nordisk product.
Results Disclaimer. Individual weight outcomes vary. The STEP 1 trial reported a mean 14.9% weight loss at week 68 in a controlled population; your result will differ based on dose, adherence, baseline weight, lifestyle, and individual response.
Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. NovoCare is a service mark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →